Management of Depression and HCV: Novel Data, Best Practices, and Case Challenges

CME-Certified Modules:

Clinical Data and Best Practices for Managing Depression in HCV-Infected Patients Treated With Peginterferon and Ribavirin Martin Schaefer, MD, highlights management strategies for patients with hepatitis C virus infection and depression, highlighting new studies from the past year.

Answering the Questions: Depression Related to HCV and Its Treatment (Coming Soon)

CME-Certified Slideset Modules:

• Clinical Data and Best Practices for Managing Depression in HCV-Infected Patients Treated With Peginterferon and Ribavirin
  In this slideset module, Martin Schaefer, MD, discusses the relationships among depression, hepatitis C virus, and treatment; management strategies for depression; the effects of hepatitis C virus on cognitive function; and management of psychiatric disorders in the setting of drug addiction.
  
• Depression Related to HCV and Its Treatment (Coming Soon)

CME-Certified Interactive Case Challenges:

	Management of a Patient With Depressive Symptoms Prior to HCV Therapy (Coming Soon)
	Management of a Patient Without a History of Depression Who Develops Psychiatric Complications During HCV Therapy (Coming Soon)
	Management of Emergent Depression and Suicidal Ideation During HCV Therapy (Coming Soon)

Minimizing Barriers and Maximizing Response: Strategies and Tools for Frontline Providers Caring for Patients With Chronic Hepatitis C

Interesting Interactive Case Challenges and Virtual Presentations that explore treatment decisions for patients with chronic hepatitis C.

Now Available!

CME/CE-Certified Interactive Case Challenges:

• Management of a Patient With Hepatitis C Genotype 1 Infection Who Relapsed After a Course of Standard Interferon and Ribavirin
  Join Tiffany A. Geahigan, PA-C, CCRC, in choosing the optimal treatment strategies for an obese black patient with genotype 1 hepatitis C who relapsed after a course of standard-dose interferon alfa and ribavirin.
• Retreatment of a Patient Failing Previous HCV Therapy
  Anne Croghan, MN, ARNP, discusses treatment options and predictors of response for patients relapsing on previous peginterferon/ribavirin therapy.
• Treatment of an HCV-Infected Patient With Advanced Disease (Coming Soon)

CME/CE-Certified Virtual Presentations:

• Minimizing Barriers and Maximizing Response: Strategies and Tools for Frontline Providers Caring for Patients With Chronic Hepatitis C
  Michael W. Fried, MD, discusses strategies to tailor hepatitis C virus treatment according to a patient’s individual response.
• Therapy for Difficult-to-Treat HCV Patients: Relapsers and Nonresponders (Coming Soon)
• Management of Hepatitis C in Advanced Liver Disease Patients (Coming Soon)

HBV Core Curriculum 2008

Now Available!

CME-Certified Virtual Presentation:

Downloadable Slideset:

Coming Soon!

CME-Certified Virtual Presentation:

HBV Election 2008: Meet the Clinical Candidates

Now Available!

CME-Certified Virtual Presentation:

New Clinical Candidates for HBV

Tram T. Tran, MD, and Robert S. Brown, Jr., MD, MPH, discuss new agents for the treatment of chronic hepatitis B and how they might fit in the treatment landscape.

CCO Slideset:

Review the new therapies for hepatitis B and the clinical issues facing these candidates. Launch Slideset

Hepatitis Annual Update 2008

Clinical Care Options' Hepatitis Annual Update offers the latest information across a wide range of hepatic issues for the optimal clinical management of your patients. Expert faculty members prepared the following CME-certified educational modules that are now available on the CCO Web site:

CME-Certified Modules:

Can Hepatitis B Be Cured? Marc G. Ghany, MD, discusses cccDNA and its role in the difficult path of obtaining a true cure for HBV infection.

Therapy of Chronic Hepatitis B: Who to Treat and When to Treat? A Case-Based Discussion Anna S. F. Lok, MD, discusses factors to consider when screening patients with chronic hepatitis B infection for treatment initiation.

Therapy of Chronic Hepatitis B: What to Choose, When to Change, and When to Stop Ira M. Jacobson, MD, reviews the latest data on which HBV therapy to choose, when to change, and when to stop.

New Data on Currently Available Hepatitis C Therapies and Their Impact on Initial Treatment Strategies Mark S. Sulkowski, MD, reviews principles and strategies for hepatitis C treatment using currently available therapeutic agents.

	Strategies for Management of Hepatitis C Treatment Failure Karen L. Lindsay, MD, MMM, reviews the latest data on the management of patients who were nonresponders or relapsers during HCV therapy.
	HCV Therapy: What Will the Future Look Like? David R. Nelson, MD, reviews investigational agents and emerging treatment strategies for hepatitis C.
	Update on Autoimmune Hepatitis: Management Strategies Michael P. Manns, MD, presents updates on the identification and clinical management of autoimmune hepatitis.
	Managing the Complications of Cirrhosis Guadalupe Garcia-Tsao, MD, reviews strategies for managing the clinical complications of cirrhosis.
	Hepatitis Journal Club: Top Clinical Articles of 2007-08 Jorge L. Herrera, MD, reviews the top hepatology articles from the past year and reviews their applications for clinical practice.

New Options for HCV Nonresponders: Navigating Emerging Data and Best Practices for Treatment-Experienced Patients

This Treatment Update is specifically designed for frontline providers, nurse practitioners, physician assistants, and others who treat patients who have been previously treated for HCV. It provides program participants with the latest data and best practices on management approaches for these patients as well as a means to synthesize these strategies through Interactive Case Challenges.

Now Available!

CME-Certified Virtual Presentation:

Downloadable Slideset:

CME-Certified Interactive Case Challenge:

Advances in HIV/HCV Coinfection

Review the most clinically relevant HIV/HCV coinfection data from the HIV/AIDS Annual Update 2008.

Now Available!

CME-Certified Module:

CCO Independent Conference Coverage of the 43rd Annual Meeting of the European Association for the Study of the Liver

Review audio Expert Highlights and Capsule Summaries of the most clinically relevant data from this important annual meeting!

CME-Certified Expert Analyses:

• Update on Hepatitis B Management
  Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF; Patrick Marcellin, MD; Norah Terrault, MD, MPH
  
• Focus on Investigational HCV Agents
  Nezam H. Afdhal, MD, FRCPI; Ira M. Jacobson, MD; Stefan Zeuzem, MD
  
• New Advances in Hepatitis C
  Alfredo Alberti, MD; Peter Ferenci, MD; Michael P. Manns, MD
  
• Highlight on Special Hepatic Issues and Populations
  Robert G. Gish, MD; Josep M. Llovet, MD; Paul Martin, MD

Now Available!

CME-Certified Expert Recaps:

Update on Hepatitis B Management Daniel Shouval, MD

Focus on Investigational HCV Agents (coming soon) Ira M. Jacobson, MD

And downloadable PowerPoint slides for review or to use in your own talks!

HIV/HCV and HIV/HBV Coinfection Highlights From the CCO Independent Conference Coverage of the 2008 Conference on Retroviruses and Opportunistic Infections

Review Capsule Summaries and a CME-certified Expert Analysis of the most clinically relevant HIV/HCV and HIV/HBV coinfection data from this important annual meeting.

CCO Independent Conference Coverage of the Conference on Hepatitis B and C Virus Resistance to Antiviral Therapies

Review the most clinically relevant viral hepatitis resistance data from this single-topic meeting with T. Jake Liang, MD, and Jean-Michel Pawlotsky, MD, PhD.

Now Available!

CME-Certified Conference Report:

Update on Resistance to HBV and HCV Therapy: CCO Independent Conference Report on the 2008 Conference on Hepatitis B and C Virus Resistance to Antiviral Therapies: T. Jake Liang, MD; Jean-Michel Pawlotsky, MD, PhD

On-Treatment Management Strategies for Chronic Hepatitis B

Now Available!

CME-Certified Interactive Case Challenge:

On-Treatment Management of a Patient With Chronic Hepatitis B Receiving Adefovir Therapy
Along with Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, choose management strategies for a patient with chronic hepatitis B receiving treatment with adefovir.

CME-Certified Virtual Presentation:

Active Management of Oral Nucleos(t)ide Analogue Therapy for Hepatitis B
Join Ira M. Jacobson, MD, as he reviews on-treatment hepatitis B virus guidelines including the relationships between early responses to oral anti-hepatitis B virus agents and future treatment outcomes.

Downloadable PowerPoint slideset available for review and use in your own educational presentations.

CCO Independent Conference Coverage of the 2007 Annual Meeting of the American Association for the Study of Liver Diseases  

CME-certified Expert Recaps:

• Clinical Updates in HBV Treatment
• Update on Investigational Agents in HCV: 2007

CME-certified Expert Analyses:

• Clinical Updates in HBV Treatment
• Advances in HCV Management Strategies With Approved Agents
• Update on Investigational Agents in HCV: 2007
• Highlight on Special Hepatic Issues and Populations

Expert Commentaries by these members of our expert faculty:

• Nezam H. Afdhal, MD, FRCPI, discusses the key studies on investigational anti-HCV agents from the Boston meeting, focusing on specifically targeted small-molecule agents and an antiparasitic demonstrating anti-HCV activity. Click here to begin.
  
  
• Raymond T. Chung, MD, reports on the most important presentations from Boston concerning predicting response to approved HCV agents and improving response of patients with poor probability of achieving sustained virologic response. In addition, he summarizes several studies of retreatment strategies for previous nonresponders. Click here to begin.
  
  
• Stephen A. Harrison, MD, LTC, MC, reviews key presentations from the Boston meeting related to insulin resistance, steatosis, and nonalcoholic steatohepatitis and their roles in the treatment of HCV. Click here to begin.
  
  
• Emmet B. Keeffe, MD, MACP, discusses several topics of interest in the field of HBV treatment, in particular, data on the use of tenofovir for the treatment of chronic HBV therapy and long-term efficacy of entecavir and baseline predictive factors for long-term treatment efficacy of telbivudine. Click here to begin.

• Choosing First-Line Therapy in Chronic Hepatitis B
  Kris Kowdley, MD, FACP, discusses the determinants for treatment candidacy, the goals of HBV therapy, and factors for selecting first-line treatment in hepatitis B. Also, access Interactive Case Challenges and a Virtual Presentation.
  
• Advanced Topics in Hepatitis C Management: Tools for Nurse Practitioners and Physician Assistants
  Review educational modules, case challenges and downloadable slides. An HCV RNA Monitoring Tool is also available.
  

• Virologic Tools for Monitoring Patients With Chronic Hepatitis B
  Use an interactive tool to tracks a patient’s progress on therapy by calculating and graphically representing changes in HBV DNA over time. The tool also generates key patient evaluation dates and interprets the patient progress over time by highlighting response patterns and tailoring responses according to treatment history. The tool has the capability to save patient data only on the end-user’s computer, making it available for editing upon subsequent uses.
  
  
• Drug Resistance in Chronic Hepatitis B: From Definitions to Management Strategies
  Access an educational module and Virtual Presentation from Emmet B. Keeffe, MD, MACP and Paul Martin, MD.
  
  
• New Management Strategies for HCV Nonresponders and Relapsers
  Join Tarek Hassanein, MD and Mitchell L. Shiffman, MD to review new data in an interactive case, downloadable slideset and an on-demand teleconference.
  
  
• Case Debates With the Experts: Applying the Updated Practice Guidelines to the Management of Hepatitis B
  Access three Interactive Case Challenges and three downloadable slidesets.
  
  
• The Future of HCV: Small Molecules in Development for Chronic Hepatitis C
  Access three educational modules by Raymond T. Chung, MD, Gary L. Davis, MD, and Kenneth E. Sherman, MD, PhD.
  

• 2008 Annual Meeting of the European Association for the Study of the Liver*
  
• 2007 Annual Meeting of the American Association for the Study of Liver Diseases*
  
  

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

• On-Treatment Management of a Patient With Chronic Hepatitis B Receiving Adefovir Therapy
  
• Management of an Overweight Man With Genotype 1 Hepatitis C 
  
• Management of a Treatment-Naive, 54-Year-Old Woman Experiencing Anemia and Virologic Breakthrough During HCV Therapy

Topics

• Fibrosis and Cirrhosis
• HBV
• HCV
• Hepatocellular Carcinoma
• HIV Coinfection
• Nash, ALD, etc.
• Other Hepatitis Viruses
• Transplantation

Resources

• Advanced Search
• Case Challenges
• Animations
• Live Events
• Slide Download Library
• Interactive Tools
• Free Bookstore

Risk Score Predicts Long-term Probability of HCC Development

A risk score using age, sex, HBV DNA levels, core promoter mutation status, and cirrhosis was created to detect 5- and 10-year probability of HCC development. More

Click here for the slide library.

Click here to visit the bookstore.

Maria Sjogren, MD, discusses the treatment management options for patients not achieving HCV RNA suppression after 24 weeks of peginterferon alfa-2b/ribavirin.

Click here for more cases.

Click here for more tools.